RNAM
Avidity Biosciences Inc
1W: -1.9%
1M: -1.7%
YTD: -1.8%
$72.86
Last traded 2026-03-03 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.3B
52W Range21.51-73.06
Volume1
Avg Volume2,697,504
Beta0.93
Dividend—
Analyst Ratings
Company Info
CEOSarah Boyce
Employees511
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-12
Websiteaviditybiosciences.com
3020 Callan Road
San Diego, CA 92121
US
San Diego, CA 92121
US
1 858 401 7900
About Avidity Biosciences Inc
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kaye Edward M. MD | D-Return | 6,692 | — | 2026-02-27 |
| Kaye Edward M. MD | D-Return | 10,034 | $33.62 | 2026-02-27 |
| Kaye Edward M. MD | D-Return | 13,489 | $39.96 | 2026-02-27 |
| Kaye Edward M. MD | D-Return | 22,000 | $12.48 | 2026-02-27 |
| Kaye Edward M. MD | D-Return | 22,000 | $12.03 | 2026-02-27 |